What is the current valuation of the ophthalmic drugs market in the GCC as of 2024?

The overall market valuation was $1122.12 Million in 2024. Read More

What is the projected market valuation for the ophthalmic drugs market in the GCC by 2035?

The projected valuation for 2035 is $2201.84 Million. Read More

What is the expected CAGR for the ophthalmic drugs market in the GCC during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.32%. Read More

Which drug class had the highest valuation in the ophthalmic drugs market in 2024?

In 2024, Glaucoma Drugs had the highest valuation at $300.0 Million. Read More

What are the key players in the ophthalmic drugs market in the GCC?

Key players include Novartis (CH), Allergan (IE), Bausch Health (CA), and Regeneron Pharmaceuticals (US), among others. Read More

Which formulation type is projected to dominate the ophthalmic drugs market in the GCC?

Eye Drops are projected to dominate with a valuation range of $600.0 Million to $1200.0 Million. Read More

What therapeutic application is expected to show significant growth in the ophthalmic drugs market in the GCC?

Dry Eye Syndrome is expected to show significant growth, with a valuation range of $448.84 Million to $880.72 Million. Read More

What route of administration is anticipated to have the highest market share in the ophthalmic drugs market?

Topical administration is anticipated to have the highest market share, valued between $672.84 Million and $1344.0 Million. Read More

How do anti-infective drugs perform in the ophthalmic drugs market in the GCC?

Anti-Infective Drugs had a valuation of $200.0 Million in 2024, with potential growth to $400.0 Million. Read More

What is the valuation range for artificial tears in the ophthalmic drugs market in the GCC?

The valuation range for Artificial Tears is $322.12 Million to $601.84 Million. Read More

GCC Ophthalmic Drugs Market

GCC Ophthalmic Drugs Market Research Report By Dosage Form (Eye Drops, Eye Ointments, Eye Solutions, Gels, Capsules Tablets, Others), By Product Type (Prescription Drug, OTC Drug), By Drug Class (Antibiotics, Anti-Inflammatory, Anti-Glaucoma, Others), By Indication (Glaucoma, Retinal Disorder, Dry Eye, Eye Allergy, Others) and By Distribution Channels (Hospital pharmacies, Drug stores, Online pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.32%

2024 Market Size

$ 1,122.12 Million

2035 Market Size

$ 2,201.84 Million

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/43561-HCR | Pages: 200 | Author: Vikita Thakur, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Drug Class (USD Million)
  1. 4.1.1 Anti-Inflammatory Drugs
  2. 4.1.2 Anti-Infective Drugs
  3. 4.1.3 Glaucoma Drugs
  4. 4.1.4 Ophthalmic Anesthetics
  5. 4.1.5 Artificial Tears
2. 4.2 Industrial Automation & Equipment, BY Formulation Type (USD Million)
  1. 4.2.1 Liquid
  2. 4.2.2 Ointment
  3. 4.2.3 Eye Drops
  4. 4.2.4 Gel
  5. 4.2.5 Sustained Release
3. 4.3 Industrial Automation & Equipment, BY Therapeutic Application (USD Million)
  1. 4.3.1 Allergic Conjunctivitis
  2. 4.3.2 Cataracts
  3. 4.3.3 Glaucoma
  4. 4.3.4 Dry Eye Syndrome
  5. 4.3.5 Intraocular Infections
4. 4.4 Industrial Automation & Equipment, BY Route of Administration (USD Million)
  1. 4.4.1 Topical
  2. 4.4.2 Intraocular
  3. 4.4.3 Systemic
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Allergan (IE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bausch Health (CA)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Regeneron Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Santen Pharmaceutical (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Hoya Corporation (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Aerie Pharmaceuticals (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GCC MARKET ANALYSIS BY DRUG CLASS
3. 6.3 GCC MARKET ANALYSIS BY FORMULATION TYPE
4. 6.4 GCC MARKET ANALYSIS BY THERAPEUTIC APPLICATION
5. 6.5 GCC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG CLASS, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY FORMULATION TYPE, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY FORMULATION TYPE, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPEUTIC APPLICATION, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPEUTIC APPLICATION, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

GCC Ophthalmic Drugs Market Segmentation

GCC Ophthalmic Drugs Market By Drug Class (USD Million, 2025-2035)

Anti-Inflammatory Drugs
Anti-Infective Drugs
Glaucoma Drugs
Ophthalmic Anesthetics
Artificial Tears

GCC Ophthalmic Drugs Market By Formulation Type (USD Million, 2025-2035)

Liquid
Ointment
Eye Drops
Gel
Sustained Release

GCC Ophthalmic Drugs Market By Therapeutic Application (USD Million, 2025-2035)

Allergic Conjunctivitis
Cataracts
Glaucoma
Dry Eye Syndrome
Intraocular Infections

GCC Ophthalmic Drugs Market By Route of Administration (USD Million, 2025-2035)

Topical
Intraocular
Systemic

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”